{"title":"Avacopan-Associated Hepatobiliary Adverse Events and Vanishing Bile Duct Syndrome: A PMDA/JADER and FAERS Reporting-Profile Comparison","authors":"Hiroteru Kamimura, Makoto Miyazawa, Shota Kaneko, Yoshihiro Uesawa, Daisuke Kobayashi, Suguru Yamamoto, Shuji Terai","doi":"10.1111/hepr.70242","DOIUrl":"10.1111/hepr.70242","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Avacopan is an oral C5a receptor antagonist approved for anti-neutrophil cytoplasmic antibody-associated vasculitis. Recent post-marketing safety information has raised concern regarding serious hepatobiliary injury, including vanishing bile duct syndrome (VBDS). We compared Japanese and FAERS post-marketing reporting profiles for avacopan-associated adverse events.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>FAERS public dashboard data and PMDA CSV data downloaded in May 2026 were searched using Japanese and English avacopan/Tavneos terms and analyzed at the case report and adverse-event/preferred-term row levels. FAERS Public Dashboard aggregate data were searched using the avacopan generic-name listing as the primary definition and the Tavneos product-name listing as a sensitivity definition.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>PMDA/JADER contained 397 avacopan-related reports and 744 adverse-event/preferred-term rows. FAERS contained 5770 reports in the avacopan generic-name listing and 5216 reports in the Tavneos product-name listing. Hepatobiliary preferred terms were prominent in PMDA/JADER, including hepatic function abnormal (<i>n</i> = 86), liver disorder (<i>n</i> = 44), drug-induced liver injury (<i>n</i> = 40), and VBDS (<i>n</i> = 29). Among PMDA/JADER VBDS reports with available dates, the median time to onset was 44.0 days (interquartile range, 39.5–52.0).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Post-marketing reports of avacopan-associated hepatobiliary injury, including VBDS, warrant clinical attention, particularly during the early treatment period. PMDA/JADER and FAERS findings should be interpreted as differences in reporting profiles rather than direct comparisons of incidence or risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1754-1760"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow-Up","authors":"Akihito Takeuchi, Atsumasa Komori, Kazuhito Kawata, Osamu Yoshida, Kazunari Tanaka, Kazumichi Abe, Yukihisa Fujinaga, Tadashi Namisaki, Naruhiro Kimura, Tomohiro Katsumi, Ryo Miura, Naoko Tachizawa, Yoshinari Asaoka, Yoshiyuki Ueno, Shuji Terai, Hiromasa Ohira, Hitoshi Yoshiji, Kentaro Kikuchi, Takeshi Matsui, Tadashi Ikegami, Akira Honda, Masanori Abe, Atsushi Tanaka","doi":"10.1111/hepr.70246","DOIUrl":"10.1111/hepr.70246","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Primary biliary cholangitis (PBC) frequently impairs health-related quality of life (HRQOL); however, longitudinal changes in symptoms and their relationship with prognosis remain unclear. We aimed to elucidate the current status of symptoms and HRQOL in Japanese patients with PBC, evaluate 10-year changes in PBC-40 scores, and examine associations with long-term outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This multicenter observational study comprised three analyses: (i) a 2025 cross-sectional study assessing associations between clinical parameters, PBC-40 (symptom indicators), and EQ-5D-5 L (HRQOL indicators); (ii) a longitudinal PBC-40 study comparing scores from 2015 to 2025; and (iii) a longitudinal outcome study evaluating 2015 PBC-40 scores and clinical parameters in relation to survival through 2025.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In 2025%, 20%–50% of all patients (<i>n</i> = 239) had moderate/severe PBC-40 scores in each domain. EQ-5D-5L scores were significantly lower in women < 59 years versus general population, with multivariable analysis identifying itch, fatigue, and social domains as independent contributors to impaired HRQOL. Across a 10-year follow-up, overall significant deterioration was observed in symptoms (<i>p</i> = 0.0015), itch (<i>p</i> = 0.0039), and cognitive (<i>p</i> = 0.0011) domains, while interindividual variability was greatest in itch and emotional and smallest in symptoms. In longitudinal outcome study (<i>n</i> = 410), no PBC-40 domain predicted death or liver transplantation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>HRQOL in patients with PBC was significantly impaired in younger female. Over 10 years, overall and interindividual changes in domain scores greatly varied, suggesting that symptom burdens are driven by heterogeneous underlying mechanisms. HRQOL impairment represents distinct dimensions of disease impact in PBC, independently of long-term outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1703-1712"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70246","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148470277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Rare Variants in PFIC-Related Genes Among Adults With Intrahepatic Cholestasis","authors":"Shunji Hirose, Kota Tsuruya, Yusuke Mishima, Yoshitaka Arase, Koichi Shiraishi, Vu Thi Hao, Satsuki Ieda, Masayuki Tanaka, Sanae Isaki, Tatehiro Kagawa","doi":"10.1111/hepr.70229","DOIUrl":"10.1111/hepr.70229","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Biallelic pathogenic variants in progressive familial intrahepatic cholestasis (PFIC)-related genes cause severe pediatric cholestasis. However, the clinical significance of heterozygous variants in adult intrahepatic cholestasis remains unclear. We investigated the prevalence of heterozygous PFIC-related gene variants in Japanese adults with intrahepatic cholestasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Whole-exome sequencing was performed in 19 adults diagnosed with intrahepatic cholestasis. Rare variants (allele frequency ≤ 0.01 in the Japanese population) predicted to be functionally damaging by in silico tools were extracted and classified according to ACMG/AMP guidelines. Allele frequencies were compared with the GEM Japan whole genome aggregation database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Four heterozygous variants in PFIC-related genes were identified in four patients (21%), and all variant carriers were diagnosed with drug-induced liver injury. One patient carried a known pathogenic <i>ABCB11</i> splice-site variant (c.908+1G>A), which was extremely rare in the Japanese reference population. The remaining variants were predicted to be functionally damaging by in silico analyses but were classified as variants of uncertain significance by ACMG criteria.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Rare variants in PFIC-related genes were identified in a subset of adults with intrahepatic cholestasis. Although all variant carriers were diagnosed with drug-induced liver injury, the clinical significance of these variants remains uncertain, particularly because most were classified as variants of uncertain significance. These findings should be considered exploratory and hypothesis-generating.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1749-1753"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70229","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148283628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Proteomic Analysis of Serum Extracellular Vesicles Revealed Fibulin-3 as a Novel Predictive Biomarker for Hepatocellular Carcinoma in Patients With Chronic Hepatitis B","authors":"Emi Sometani, Kazuhiro Murai, Hayato Hikita, Jihyun Sung, Satoshi Muraoka, Hidenori Toyoda, Satoshi Tanaka, Takayuki Miyake, Shinji Kuriki, Kenji Fukumoto, Satoshi Shigeno, Yuta Myojin, Kazuki Maesaka, Kumiko Shirai, Yuki Makino, Yuki Tahata, Yoshinobu Saito, Takahiro Kodama, Ryotaro Sakamori, Jun Adachi, Tomomi Yamada, Tetsuo Takehara","doi":"10.1111/hepr.70234","DOIUrl":"10.1111/hepr.70234","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Although nucleos(t)ide analog (NUC) therapy reduces hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients, HCC can develop despite viral suppression. Identifying predictive biomarkers of HCC during NUC therapy remains clinically important. This study aimed to identify novel biomarkers by proteomic analysis of serum extracellular vesicle (EV) proteins in CHB patients receiving NUC therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We enrolled 242 CHB patients treated with NUCs for over one year, with serum HBV DNA < 3.0 log IU/mL, no prior HCC, and available stored serum samples. Proteomic analysis of serum EV proteins was carried out to identify candidate biomarkers, followed by validation of their serum levels using enzyme-linked immunosorbent assay (ELISA).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age was 55 years; 144 were male. During a median follow-up of 10.1 years, 44 patients (18.2%) developed HCC. Five candidate EV proteins were identified: fibulin-3, VCAM-1, fibronectin, vWF, and FGFBP2. In univariate Cox analysis of serum levels of candidate EV proteins measured by ELISA, fibulin-3 and VCAM-1 were identified as significant predictive factors. In multivariate analysis, male sex, GGT, AFP, fibulin-3, and the FIB-4 index were independent predictors, whereas VCAM-1 was not. A cutoff value for fibulin-3 was set at 10.8 μg/mL. HCC incidence was significantly higher in patients with fibulin-3 ≥ 10.8 μg/mL and in those with ≥ 3 of five identified risk factors. The 10-year cumulative HCC incidence was 0% versus 37.2% in patients with 0 versus ≥ 3 risk factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Serum fibulin-3 is a novel biomarker predictive of HCC in CHB patients undergoing NUC therapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1614-1631"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70234","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Development of a Risk-Estimation Model for Identifying Patients at Risk of Early Skeletal Muscle Mass Loss in Chronic Liver Disease","authors":"Atsushi Hiraoka, Hideko Ohama, Fujimasa Tada, Kazuhiro Tange, Osamu Yoshida, Masashi Hirooka, Masanori Abe, Tomoyuki Ninomiya, Sachiyo Yoshio, Yoichi Hiasa","doi":"10.1111/hepr.70245","DOIUrl":"10.1111/hepr.70245","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Sarcopenia is associated with poor outcomes in patients with chronic liver disease (CLD), but current screening based on reduced muscle strength may fail to identify early skeletal muscle loss. This study aimed to develop a risk-estimation model for identifying patients at risk of early skeletal muscle mass loss before patients meet the diagnostic criteria for overt sarcopenia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective study included 1276 CLD patients who underwent handgrip strength testing and computed tomography-based skeletal muscle index (SMI) assessment between 2015 and 2026. SMI ratio and grip ratio were defined as relative deviations from sex-specific reference values established by the Japan Society of Hepatology. Early skeletal muscle mass loss was defined as an SMI ratio < 0.05. A multivariable logistic regression model incorporating grip ratio, age, sex, platelet count, albumin-bilirubin score, creatinine, body mass index, hepatocellular carcinoma status, and the interaction between grip ratio and sex was developed (MYO-SCAN score).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The model demonstrated good discrimination for identifying patients with an SMI ratio < 0.05 with an area under the receiver operating characteristic curve (AUC) of 0.847. The optimal cutoff value was 0.435, yielding sensitivity and specificity of 0.777 and 0.764, respectively. Risk-estimation performance was significantly superior to grip ratio alone (AUC 0.847 vs. 0.614, <i>p</i> < 0.001). Bootstrap validation showed minimal optimism with an optimism-corrected AUC of 0.843.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The MYO-SCAN score may facilitate early identification of CLD patients at risk of skeletal muscle mass loss, including those who may be overlooked by grip-strength–based screening.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1696-1702"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis","authors":"Ryohei Tanigawa, Yoshiyuki Ueno, Hirokazu Takahashi, Ayumi Saito, Hideki Suganami, Atsushi Tanaka","doi":"10.1111/hepr.70244","DOIUrl":"10.1111/hepr.70244","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aim</h3>\u0000 \u0000 <p>Pemafibrate, a selective PPARα modulator (SPPARMα), improves cholestatic liver enzymes in primary biliary cholangitis (PBC). However, whether these effects depend on PBC-specific autoimmune mechanisms or reflect broader anti-cholestatic actions remains unclear. This study evaluated the effects of pemafibrate on cholestatic markers by PBC status and explored bile acid and immunological changes in patients with PBC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This post hoc analysis used data from a 52-week phase III study of pemafibrate in patients with hypertriglyceridemia, including 9 with PBC. Cholestatic markers (ALP, total bilirubin, GGT, and LAP) were assessed serially. Linear regression examined associations between baseline levels and response by PBC status. In patients with PBC, bile acids, FGF19, FGF21, C4, IgM, IgG, and M2BPGi were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pemafibrate significantly reduced all cholestatic markers from week 4–52, regardless of the presence of PBC. Greater reductions were observed in patients with higher baseline levels. In patients with PBC, C4 decreased without significant change in FGF19, suggesting suppression of de novo bile acid synthesis independent of intestinal feedback. The bile acid profile shifted toward a more hydrophilic composition with reduced hydrophobic species. IgM, IgG, and M2BPGi decreased, whereas FGF21 increased.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Pemafibrate improved cholestatic markers in a baseline-dependent manner, regardless of the presence of PBC, suggesting mechanisms beyond PBC-specific pathology. These findings support a broader anti-cholestatic effect, potentially mediated by coordinated modulation of bile acid metabolism and immunological activity through PPARα activation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>The trials were registered at ClinicalTrials.gov under the identifiers NCT04716595</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1685-1695"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70244","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Potential Role of Liver Transplantation for Child–Pugh Class A Hepatocellular Carcinoma: Prognosis and Medical Expenditure in Japan—A Retrospective Single-Center Study","authors":"Akihiro Seki, Tomoyoshi Chiba, Shintaro Yagi, Rika Horii, Noboru Takata, Hiroki Nomura, Masaki Miyazawa, Tomoyuki Hayashi, Takeshi Terashima, Shinichi Nakanuma, Mitsuyoshi Okazaki, Satoshi Takada, Tatsuya Yamashita, Masao Honda, Hajime Takatori, Tetsuro Shimakami, Taro Yamashita","doi":"10.1111/hepr.70230","DOIUrl":"10.1111/hepr.70230","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>In Japan, liver transplantation (LT) for hepatocellular carcinoma (HCC) is restricted to patients with decompensated cirrhosis. We investigated the clinical course, prognosis, and medical expenditure of patients with Child–Pugh class A (CP-A) HCC initially within the Japan criteria, including changes in oncological eligibility for LT during follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed patients with HCC treated at Kanazawa University Hospital between 2011 and 2021. After applying the age criterion (< 70 years), 134 patients with CP-A HCC, 45 with CP-B HCC, and 6 LT recipients were included. Survival and cumulative HCC-related medical expenditures were compared. A transplantable period was defined as the interval during which both hepatic reserve and tumor burden met LT eligibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>LT achieved the most favorable prognosis, with a 5-year overall survival rate of 83.3%. Among patients with CP-A HCC, progression beyond the Japan criteria was associated with markedly reduced survival, approaching that observed in CP-B disease. Of 53 patients who progressed beyond the Japan criteria, only 12 (22.6%) retained a transplantable period (median, 10.6 months). Early recurrence and a FIB-4 index > 5 were independently associated with poor prognosis. The cost per treatment life-year did not differ significantly between LT recipients and certain CP-A HCC subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Many patients with CP-A HCC initially within the Japan criteria lost oncological eligibility for LT before hepatic decompensation. Further studies are warranted to determine whether a subset of patients with compensated cirrhosis may benefit from LT and to inform future discussions regarding the potential expansion of LT indications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1586-1595"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hepr.70230","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Statin Use Is Associated With Improved Survival But Not Progression-Free Outcomes in Patients With Unresectable Hepatocellular Carcinoma Receiving Atezolizumab–Bevacizumab","authors":"Toshinori Toyota, Satoshi Narahara, Haruki Uojima, Yuki Kitano, Takahiro Mizuta, Daiki Maeda, Soutarou Kurano, Kentaro Tanaka, Hiroki Inada, Munenori Honda, Yoko Yoshimaru, Takehisa Watanabe, Katsuya Nagaoka, Hiroko Setoyama, Hiromitsu Hayashi, Takanori Suzuki, Kentaro Matsuura, Shuichiro Iwasaki, Nao Nomura, Shiho Miyase, Hideto Yuruki, Yoshinari Sakai, Koichi Kudo, Hisashi Hidaka, Masaaki Iwatsuki, Yasuhito Tanaka","doi":"10.1111/hepr.70232","DOIUrl":"10.1111/hepr.70232","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Statins contribute to the preservation of hepatic function and reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic liver disease; however, their clinical significance during systemic therapy for unresectable HCC remains unclear. Therefore, we investigated whether baseline statin use influences clinical outcomes in patients with unresectable HCC treated with atezolizumab plus bevacizumab.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a multicenter, retrospective cohort study of patients with unresectable HCC treated with atezolizumab–bevacizumab. Patients were classified as statin users or non-users at treatment initiation. The primary outcome was overall survival (OS), and secondary outcomes included progression-free survival (PFS) and post-progression survival (PPS). To adjust for baseline imbalances, inverse probability of treatment weighting (IPTW) was applied, and propensity score (PS) matching was performed as a sensitivity analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 284 patients were included, of whom 50 received statins. In the unadjusted cohort, OS was significantly longer in statin users than in non-users (<i>p</i> = 0.026). After IPTW adjustment, this OS benefit remained significant (<i>p</i> = 0.031). In contrast, PFS did not differ significantly between groups in either the unadjusted (<i>p</i> = 0.291) or IPTW-adjusted cohorts (<i>p</i> = 0.117). PPS was significantly prolonged in the statin group (<i>p</i> = 0.006), with consistent findings after IPTW adjustment (<i>p</i> = 0.018). In addition, deterioration in ALBI score was attenuated in statin users, suggesting better preservation of hepatic functional reserve.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Statin use was associated with significantly improved OS and PPS without affecting PFS, likely reflecting host-related benefits through preservation of hepatic function.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1596-1605"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Impact of the Number of Remaining Natural Teeth on Decompensation and Survival in Patients With Compensated Liver Cirrhosis","authors":"Tatsuya Nakatani, Tadashi Namisaki, Hiroaki Takaya, Takashi Inoue, Akihiko Shibamoto, Satoshi Iwai, Masafumi Oyama, Junichi Hanatahi, Naoki Nishimura, Yuki Tsuji, Yukihisa Fujinaga, Shinya Sato, Norihisa Nishimura, Koh Kitagawa, Kosuke Kaji, Akira Mitoro, Takemi Akahane, Hitoshi Yoshiji","doi":"10.1111/hepr.70243","DOIUrl":"10.1111/hepr.70243","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>To evaluate the impact of oral health, measured by the number of remaining natural teeth, on hepatic decompensation and survival in patients with compensated liver cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study included 106 patients with Child–Pugh class A cirrhosis who were followed longitudinally until March 2024. Patients were stratified by number of remaining natural teeth with fewer than 20 teeth classified as poor oral health according to the concept of functional dentition. Cox proportional hazards models were used to identify factors associated with hepatic decompensation and overall survival. Associations between tooth number, sarcopenia, and endotoxin activity were also evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>During follow-up, 26 patients developed hepatic decompensation and 26 died. Kaplan–Meier analysis showed that patients with fewer than 20 remaining natural teeth had significantly higher rates of hepatic decompensation and poorer overall survival than those retaining 20 or more teeth. In multivariate analysis, fewer than 20 teeth were independently associated with hepatic decompensation (hazard ratio [HR]: 2.46; 95% confidence interval [CI], 1.08–5.40; <i>p</i> = 0.032) and mortality (HR: 2.32; 95% CI, 1.01–5.34; <i>p</i> = 0.048). Patients with fewer teeth exhibited a higher prevalence of sarcopenia and significantly increased endotoxin activity.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Severe tooth loss was independently associated with hepatic decompensation and mortality in compensated cirrhosis. Oral health assessment using the number of remaining natural teeth may provide a simple and clinically valuable tool for prognostic stratification in patients with cirrhosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1676-1684"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148430382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Childhood Underweight and Adulthood Obesity Associated With Increased Risk of MASLD and Cirrhosis: A Prospective Cohort Study of 375,125 Adults","authors":"Jiadong Zeng, Jian Liang, Hao Zhang, Hanming Wang, zheyang Lin, Wenzhe Zhang, Haobin Zhang, Xudong Deng, Jiahui Lin, Minqi Liu, Minwen Chen, Yue Qiu, Zhen Zhang, Zhaohua Zhu, Yi Zeng","doi":"10.1111/hepr.70238","DOIUrl":"10.1111/hepr.70238","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Obesity is a known risk factor for metabolic dysfunction–associated steatotic liver disease (MASLD) and cirrhosis, but the long-term effects of childhood thinness and body size changes across life are unclear. We aimed to assess how body size and child-to-adult body size trajectories relate to major liver outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We studied 375,125 UK Biobank participants without liver disease at baseline. Childhood body size (thinner, average, and plumper) and adulthood body size (normal, overweight, and obesity) were combined into nine trajectories. Cox models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for incident MASLD and cirrhosis. Kaplan–Meier survival curves assessed the association between body size trajectories and liver diseases. Sensitivity and subgroup analyses tested robustness.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with average childhood body size, childhood thinness was associated with higher risks of MASLD (HR 1.18, 95% CI 1.11–1.27) and cirrhosis (HR 1.15, 95% CI 1.03–1.27). Relative to persistently normal body size, the “thinner to obesity” trajectory showed the greatest risks of MASLD (HR 3.95, 95% CI 3.29–4.76) and cirrhosis (HR 3.97, 95% CI 3.30–4.77). The “plumper to normal” trajectory was not associated with increased MASLD or cirrhosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Childhood thinness is associated with increased risks of MASLD and cirrhosis in adulthood. Achieving a normal BMI in adulthood may mitigate liver-related risks linked to childhood overweight.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12987,"journal":{"name":"Hepatology Research","volume":"56 11","pages":"1643-1653"},"PeriodicalIF":3.7,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148455330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}